What is the appropriate workup and diagnostic criteria for polycystic ovary syndrome in a reproductive‑age woman presenting with menstrual irregularities and signs of hyperandrogenism?

PCOS Workup and Diagnosis

Diagnose PCOS using the Rotterdam criteria: any 2 of 3 features—hyperandrogenism (clinical or biochemical), ovulatory dysfunction, or polycystic ovaries on ultrasound—after excluding thyroid disease, hyperprolactinemia, and nonclassic congenital adrenal hyperplasia. 1

Diagnostic Criteria

The Rotterdam criteria provide the most widely endorsed framework for PCOS diagnosis in reproductive-age women. You need to document two of the following three features 1:

• Androgen excess: Clinical (hirsutism, acne, alopecia) or biochemical (elevated testosterone)
• Ovulatory dysfunction: Oligomenorrhea or amenorrhea (menstrual cycles >35 days apart or <8 cycles per year)
• Polycystic ovaries: ≥12 follicles measuring 2-9 mm or ovarian volume >10 mL on ultrasound (in absence of dominant follicle >10 mm)

Important caveat: If the patient already meets two criteria clinically (e.g., irregular periods plus hirsutism), you do not need to order androgen assays or ultrasound—the diagnosis can be made on clinical grounds alone 1.

Required Exclusion Testing

All women must be screened for conditions that mimic PCOS 1:

• TSH: Excludes thyroid disease causing menstrual irregularity
• Prolactin: Excludes hyperprolactinemia (can present with amenorrhea or hirsutism)
• 17-hydroxyprogesterone (17-OHP): Excludes nonclassic congenital adrenal hyperplasia (found in 1.5-6.8% of hyperandrogenic patients)

Extended Workup for Select Patients

Order additional testing only in women with 1:

• Amenorrhea (not just oligomenorrhea)
• Virilization (clitoromegaly, voice deepening, severe acne)
• Atypical features: Proximal muscle weakness (Cushing's), frontal bossing (acromegaly), rapid onset symptoms (androgen-secreting tumor)

These patients require evaluation for Cushing's syndrome, acromegaly, and androgen-secreting tumors.

Physical Examination Essentials

Document the following cutaneous manifestations 1:

• Terminal hair growth pattern and severity (use Ferriman-Gallwey score if available)
• Acne distribution and severity
• Androgenic alopecia (temporal or vertex thinning)
• Acanthosis nigricans (neck, axillae, groin—indicates insulin resistance)
• Skin tags

Ovulatory Status Assessment

Screen ovulatory status using menstrual history as the primary tool 1:

• Cycles >35 days apart or <8 cycles/year indicate anovulation
• For women with regular cycles who are seeking fertility, consider midluteal progesterone (day 21-23 of 28-day cycle) as some PCOS patients with regular menses still experience anovulation

Special Population Considerations

Adolescents: Diagnosis requires persistent oligomenorrhea (>2 years post-menarche) plus hyperandrogenism (clinical or biochemical). Do not use ovarian morphology or AMH levels—these overlap with normal pubertal development 1, 2, 3.

Perimenopausal women: Diagnosis can be presumptive based on well-documented history of oligomenorrhea and hyperandrogenism during reproductive years. Ultrasound findings are less reliable in this age group 1.

Common Pitfalls to Avoid

• Don't over-test: If clinical criteria are met (irregular periods + hirsutism), additional biochemical or ultrasound testing is unnecessary for diagnosis
• Don't diagnose adolescents prematurely: Irregular cycles are normal for 2 years post-menarche; ovarian morphology is unreliable in this age group
• Don't skip exclusion labs: Missing nonclassic CAH or thyroid disease leads to inappropriate treatment
• Don't forget metabolic screening: While not part of diagnostic criteria, assess for diabetes risk (fasting glucose, HbA1c, or OGTT) and cardiovascular risk factors given the strong metabolic associations 4, 5

Documentation Requirements

Record which specific features led to the diagnosis (e.g., "oligomenorrhea + biochemical hyperandrogenism" or "hirsutism + polycystic ovaries on ultrasound") 1. This phenotypic documentation matters because different PCOS phenotypes carry different metabolic and reproductive risk profiles—hyperandrogenism associates more strongly with metabolic abnormalities, while ovulatory dysfunction correlates more with infertility 1.